The Epidural and Intrathecal Administration of Somatotrophin-release Inhibiting Factor: Native and Synthetic Analogues

Overview

Journal Curr Rev Pain

Publisher Current Science

Specialty Neurology

Date 2000 Sep 22

PMID 10998719

Authors

D P Beltrutti

S Moessinger

G Varrassi

Affiliations

Soon will be listed here.

Abstract

It is well-known that morphine is the king of analgesics. It is widely used, and administered in various ways for the control of acute and chronic pain states. There are, however, certain types of pain and certain clinical conditions in which morphine cannot be used due to the risk of possible complications. These are usually pain states associated with intracranial hypertension, the presence of serious respiratory problems, the onset of major opioid tolerance, persistent vomiting, and so on. The search for "alternative analgesics" has been in progress for a decade, alternatives that could be used alone or in combination for spinal administration in the treatment of complex chronic pain states and with a low incidence of secondary effects. Today, research is carefully assessing the clinical effectiveness and the side effects of a series of drugs for spinal administration, that is, epidural or intrathecal, such as the new narcotics, alpha-2 agonists, central muscle relaxants, calcitonin, and local anesthetics. In this alternative analgesic category we have to mention the somatotrophin-release inhibiting factor (SRIF), which is an ubiquitous native hormone with widespread, predominantly inhibitory actions, and octreotide, its synthetic analogue. In this article we review the literature on the natural drug and its synthetic analogue, paying particular attention to the problems connected with intraspinal administration and analgesic properties.

References

Chrubasik J . [Somatostatin. A review]. Anasth Intensivther Notfallmed. 1985; 20(4):165-70. View

Tulassay Z, Gupta R, Papp J, Bodnar A . Somatostatin versus cimetidine in the treatment of actively bleeding duodenal ulcer: a prospective, randomized, controlled trial. Am J Gastroenterol. 1989; 84(1):6-9. View

Hasler W, Soudah H, Owyang C . A somatostatin analogue inhibits afferent pathways mediating perception of rectal distention. Gastroenterology. 1993; 104(5):1390-7. DOI: 10.1016/0016-5085(93)90347-f. View

Chrubasik J . Intrathecal somatostatin. Ann N Y Acad Sci. 1988; 531:133-45. DOI: 10.1111/j.1749-6632.1988.tb31819.x. View

Berger V, Alloui A, Kemeny J, Dubray C, Eschalier A, Lavarenne J . Evidence for a role for bulbospinal pathways in the spinal antinociceptive effect of systemically administered vapreotide in normal rats. Fundam Clin Pharmacol. 1998; 12(2):200-4. DOI: 10.1111/j.1472-8206.1998.tb00942.x. View

Havlicek V, Rezek M, Friesen H . Somatostatin and thyrotropin releasing hormone: central effect on sleep and motor system. Pharmacol Biochem Behav. 1976; 4(4):455-9. DOI: 10.1016/0091-3057(76)90063-0. View

Chihara K, Arimura A, Chihara M, Schally A . Effect of intraventricular administration of anti-somatostatin gamma-globulin on the lethal dose-50 of strychnine and pentobarbital in rats. Endocrinology. 1978; 103(3):912-6. DOI: 10.1210/endo-103-3-912. View

Mollenholt P, Post C, Rawal N, Freedman J, Hokfelt T, Paulsson I . Antinociceptive and 'neurotoxic' actions of somatostatin in rat spinal cord after intrathecal administration. Pain. 1988; 32(1):95-105. DOI: 10.1016/0304-3959(88)90028-0. View

Masuda M, Kanai S, Miyasaka K, Funakoshi A . Somatostatin inhibits pancreatic exocrine secretion centrally via sympathetic nerves in conscious rats. J Auton Nerv Syst. 1995; 56(1-2):31-7. DOI: 10.1016/0165-1838(95)00057-9. View

10.

Schulz S, Schreff M, Schmidt H, Handel M, Przewlocki R, Hollt V . Immunocytochemical localization of somatostatin receptor sst2A in the rat spinal cord and dorsal root ganglia. Eur J Neurosci. 1999; 10(12):3700-8. DOI: 10.1046/j.1460-9568.1998.00386.x. View

11.

Swerdlow M . General analgesics used in pain relief: pharmacology. Br J Anaesth. 1967; 39(9):699-712. DOI: 10.1093/bja/39.9.699. View

12.

Brodin E, Gazelius B, Lundberg J, Olgart L . Substance P in trigeminal nerve endings: occurrence and release. Acta Physiol Scand. 1981; 111(4):501-3. DOI: 10.1111/j.1748-1716.1981.tb06770.x. View

13.

Penn R, Paice J, Kroin J . Octreotide: a potent new non-opiate analgesic for intrathecal infusion. Pain. 1992; 49(1):13-19. DOI: 10.1016/0304-3959(92)90182-B. View

14.

DAlessandro R, De Filippo M, Pascali S, Racano L, Santoprete E . [Treatment of postoperative pain with peridural octreotide. Our experience]. Minerva Anestesiol. 1991; 57(10):1098-9. View

15.

Raynor K, Reisine T . Somatostatin receptors. Crit Rev Neurobiol. 1992; 6(4):273-89. View

16.

Gonzalez B, Leroux P, Lamacz M, Bodenant C, Balazs R, Vaudry H . Somatostatin receptors are expressed by immature cerebellar granule cells: evidence for a direct inhibitory effect of somatostatin on neuroblast activity. Proc Natl Acad Sci U S A. 1992; 89(20):9627-31. PMC: 50185. DOI: 10.1073/pnas.89.20.9627. View

17.

Moore R, Bullingham R, McQuay H, Hand C, Aspel J, Allen M . Dural permeability to narcotics: in vitro determination and application to extradural administration. Br J Anaesth. 1982; 54(10):1117-28. DOI: 10.1093/bja/54.10.1117. View

18.

Harfstrand A, Kalia M, Fuxe K, Kaijser L, Agnati L . Somatostatin-induced apnea: interaction with hypoxia and hypercapnea in the rat. Neurosci Lett. 1984; 50(1-3):37-42. DOI: 10.1016/0304-3940(84)90458-0. View

19.

Hill J, McCune S, Alvero R, Glazner G, Henins K, Stanziale S . Maternal vasoactive intestinal peptide and the regulation of embryonic growth in the rodent. J Clin Invest. 1996; 97(1):202-8. PMC: 507080. DOI: 10.1172/JCI118391. View

20.

Gaumann D, Yaksh T . Intrathecal somatostatin in rats: antinociception only in the presence of toxic effects. Anesthesiology. 1988; 68(5):733-42. View